Rothschild cuts Moderna to Sell from Neutral, analyst note
Rothschild & Co analyst Simon Baker cut Moderna from Neutral to Sell in a research note Thursday, marking the company’s second Sell rating. The downgrade was described as having little link to commercial potential or pipeline prospects.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.